Phaseline

Companies › NeoTX Therapeutics

NeoTX Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Naptumomab estafenatox
Trophoblast glycoprotein other
TPBGPhase 1ER+ Breast CancerMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03983954Naptumomab estafenatoxPhase 1ER+ Breast CancerOncologyMar 2027

Targets

TPBG (1)

Companies with the same targets

Salubris Biotherapeutics Qilu Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.